slides · global inventory
Paragraph
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 118,578
Current window 99,991-100,020
Pages 3,953
Rows per page 30
Component
99,991-100,020 of 118,578
09
The slide uses a dual-track timeline to show acquisitions (Luxury) vs divestments (Non-Luxury).Kering | Fixed Income Presentation Deck | 35 slides · Kering
Deck Investor relations Beat · Solution1 hit
01
Kering | Investor Presentation Deck | 63 slidesKering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations 1 hit
09
The slide uses a before-and-after comparison of strategic focus (pie charts) and provides a concrete implementation plan for 'Elevation strategy'.Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Aha Moment1 hit
29
The slide highlights alignment with SBTi, Fashion Pact, RE100, CDP, and TCFD.Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
40
Kering | Investor Presentation Deck | 63 slidesKering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations 1 hit
54
The slide uses a waterfall chart to bridge revenue between H1 2022 and H1 2023, highlighting contributions from Retail, Wholesale, and Royalties.Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations 1 hit
62
Kering | Investor Presentation Deck | 63 slidesKering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations 1 hit
01
Includes company logo and date.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
08
Includes a biological pathway diagram and a specific 'Degrader Advantage' callout box.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
14
Includes error bars representing standard error of the mean; data points are plotted over 42 days.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
18
The slide highlights a favorable safety profile with no serious adverse events (SAEs) or drug-related infections.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
20
Includes clinical trial identifiers and definitions of acronyms in the footer.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
25
The table displays adverse events occurring in 2 or more patients. Data includes patient counts and percentages for both 'All' and 'Related' adverse events.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
30
The slide uses a split-layout: left side for clinical data results, right side for strategic positioning.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
38
Clinical trial safety reporting slide.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
10
The slide displays two dot plots with error bars representing median and 25th/75th percentiles for FXN concentration changes from baseline.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
11
The slide outlines the methodology for a clinical trial, specifically focusing on the 28-day treatment schedule and cohort details.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
12
Data represents median and 25th/75th percentiles. Baseline values provided in footnotes.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
13
The slide establishes a baseline for FXN levels in healthy individuals to contextualize the deficiency seen in Friedreich's Ataxia (FA) patients.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
14
The slide highlights high completion rates and manageable adverse events, specifically noting injection site reactions (ISRs) as the most common side effect.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
15
FACOMS: Friedreich's Ataxia Clinical Outcome Measures StudyLarimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
16
The slide outlines a clinical development roadmap with specific trial types and status updates.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
25
The slide outlines the clinical trial methodology for a drug candidate in Friedreich's Ataxia (FA) patients.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
27
The charts display median values with 25th and 75th percentile error bars.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
30
The slide highlights the safety profile of the drug candidate, specifically noting the absence of serious adverse events and the nature of injection site reactions.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
33
The slide outlines a 28-day treatment schedule with specific administration days highlighted in green.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
36
The slide highlights that demographics are similar between Phase 1 and Phase 2 trials.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
38
Larimar Therapeutics | Investor Presentation Deck | 44 slidesLarimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
40
Kaplan-Meier survival curve showing efficacy of FXN replacement therapy.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
41
The slide highlights key preclinical efficacy outcomes for the drug candidate CTI-1601.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit